Effects of short-term testosterone administration on variables of the metabolic syndrome., in particular aldosterone

Hormone Molecular Biology and Clinical Investigation

Volumn 12, Issue 2, 2012, Pages 401-406

  Goncharov, Nikolay P ^a   Goncharov, Nikolay ^a   Katsya, Gulinara ^a   Gaivoronskaya, Lidiya ^b   Zoloedov, Vladimir ^b   Uskov, Valentin ^c   Gooren, Louis ^d  

^a ENDOCRINOLOGY RESEARCH CENTRE   (Russian Federation)

^b State Medical Academy   (Russian Federation)

^c City Clinical Hospital No 20   (Russian Federation)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

aldosterone; chronic heart failure; insulin; metabolic syndrome; testosterone

Indexed keywords

ALDOSTERONE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL; UNDECANOIC ACID;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; ECHOCARDIOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; MALE; MEDICAL HISTORY; METABOLIC SYNDROME X; MIDDLE AGED; PRIORITY JOURNAL; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84878821590     PISSN: 18681883     EISSN: 18681891     Source Type: Journal    
DOI: 10.1515/hmbci-2012-0023     Document Type: Article

References (56)

1. Wu FC., von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003;24:183-217.
2. Liu PY., Death AK., Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003;24:313-40.
3. Jones RD., Nettleship JE., Kapoor D., Jones HT., Channer KS. Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs 2005;5:141-54.
4. Shabsigh R., Rajfer J., Aversa A., Traish AM., Yassin A., Kalinchenko SY., Buvat J. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract 2006;60:1087-92.
5. Shabsigh R., Katz M., Yan G., Makhsida N. Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 2005;96:67M-72M.
6. Corona G., Forti G., Maggi M. Why can patients with erectile dysfunction be considered lucky? The association with testosterone deficiency and metabolic syndrome. Aging Male 2008;11:193-9.
7. Traish AM., Saad F., Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009;30:23-32.
8. Yassin AA., Saad F., Gooren LJ. The metabolic syndrome., testosterone deficiency and erectile dysfunction never come alone. Andrologia 2008;40:259-64.
9. Corona G., Mannucci E., Forti G., Maggi M. Hypogonadism., ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases. Int J Androl 2009;32:587-98.
10. Khaw KT., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N. Endogenous testosterone and mortality due to all causes., cardiovascular disease., and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694-701.
11. Shores MM., Moceri VM., Gruenewald DA., Brodkin KI., Matsumoto AM., Kivlahan DR. Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 2004;52:2077-81.
12. Shores MM., Matsumoto AM., Sloan KL., Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5.
13. Laughlin GA., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
14. Maggio M., Lauretani F., Ceda GP., Bandinelli S., Ling SM., Metter EJ., Artoni A., Carassale L., Cazzato A., Ceresini G., Guralnik JM., Basaria S., Valenti G., Ferrucci L. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007;167:2249-54.
15. Tibblin G., Adlerberth A., Lindstedt G., Bjorntorp P. The pituitary-gonadal axis and health in elderly men: a study of men born in 1913. Diabetes 1996;45:1605-9.
16. Malkin CJ., Pugh PJ., Morris PD., Asif S., Jones TH., Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-5.
17. Corona G., Monami M., Rastrelli G., Aversa A., Tishova Y., Saad F., Lenzi A., Forti G., Mannucci E., Maggi M. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011;8:272-83.
18. Brand JS., van der Tweel I., Grobbee DE., Emmelot-Vonk MH., van der Schouw YT. Testosterone., sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 2011; 40:189-207.
19. Blouin K., Despres JP., Couillard C., Tremblay A., Prud'homme D., Bouchard C., Tchernof A. Contribution of age and declining androgen levels to features of the metabolic syndrome in men. Metabolism 2005;54:1034-40.
20. Kalme T., Seppala M., Qiao Q., Koistinen R., Nissinen A., Harrela M., Loukovaara M., Leinonen P., Tuomilehto J. Sex hormone-binding globulin and insulin-like growth factor-binding protein-1 as indicators of metabolic syndrome., cardiovascular risk., and mortality in elderly men. J Clin Endocrinol Metab 2005;90:1550-6.
21. Kupelian V., Page ST., Araujo AB., Travison TG., Bremner WJ., McKinlay JB. Low sex hormone-binding globulin., total testosterone., and symptomatic androgen deficiency are associated with development of the metabolic syndrome in non-obese men. J Clin Endocrinol Metab 2006;91:843-50.
22. Laaksonen DE., Kainulainen S., Rissanen A., Niskanen L. Relationships between changes in abdominal fat distribution and insulin sensitivity during a very low calorie diet in abdominally obese men and women. Nutr Metab Cardiovasc Dis 2003;13:349-56.
23. Muller M., Grobbee DE., den Tonkelaar I., Lamberts SW., van der Schouw YT. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;90:2618-23.
24. Saad F., Gooren LJ. The role of testosterone in the etiology and treatment of obesity., the metabolic syndrome., and diabetes mellitus type 2. J Obes 2011;pii:471584.
25. Traish AM., Kypreos KE. Testosterone and cardiovascular disease: an old idea with modern clinical implications. Atherosclerosis 2010;214:244-8.
26. Kaplan SA., Meehan AG., Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006;176:1524-7; discussion 1527-8.
27. Allan CA., Strauss BJ., Burger HG., Forbes EA., McLachlan RI. The association between obesity and the diagnosis of androgen deficiency in symptomatic ageing men. Med J Aust 2006;185:424-7.
28. Kalyani RR., Dobs AS. Androgen deficiency., diabetes, and the metabolic syndrome in men. Current Opin Endocrinol Diabetes Obes 2007;14:226-34.
29. Allan CA., Strauss BJ., McLachlan RI. Body composition., metabolic syndrome and testosterone in ageing men. Int J Impot Res 2007;19:448-57.
30. Mohr BA., Bhasin S., Link CL., O'Donnell AB., McKinlay JB. The effect of changes in adiposity on testosterone levels in older men: longitudinal results from the Massachusetts Male Aging Study. Eur J Endocrinol 2006;155:443-52.
31. Rodriguez A., Muller DC., Metter EJ., Maggio M., Harman SM., Blackman M.R., Andres R. Aging., androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007;92:3568-72.
32. Svartberg J., von Muhlen D., Sundsfjord J., Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 2004;19:657-63.
33. Roberge C., Carpentier AC., Langlois MF., Baillargeon JP., Ardilouze JL., Maheux P., Gallo-Payet N. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. Am J Physiol Endocrinol Med 2007;293:E1465-78.
34. Krug AW., Ehrhart-Bornstein M. Aldosterone and metabolic syndrome: is increased aldosterone in metabolic syndrome patients an additional risk factor? Hypertension 2008;51:1252-8.
35. Catena C., Lapenna R., Baroselli S., Nadalini E., Colussi G., Novello M., Favret G., Melis A., Cavarape A., Sechi LA. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metabol 2006;91:3457-63.
36. Stas S., Whaley-Connell A., Habibi J., Appesh L., Hayden M.R., Karuparthi PR., Qazi M., Morris EM., Cooper SA., Link CD., Stump C., Hay M., Ferrario C., Sowers JR. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology 2007;148:3773-80.
37. Goncharov N., Kolesnikova G., Bydrova S. Quantitative and qualitative parameters of an adrenal steroidogenesis in obese women of reproductive age. Prob Endocrinol 2008;6:16-21.
38. Hannemann A., Meisinger C., Bidlingmaier M., Doring A., Thorand B., Heier M., Belcredi P., Ladwig KH., Wallaschofski H., Friedrich N., Schipf S., Ludemann J., Rettig R., Peters J., Volzke H., Seissler J., Beuschlein F., Nauck M., Reincke M. Association of plasma aldosterone with the metabolic syndrome in two German populations. Eur J Endocrinol 2011;164:751-8.
39. Briet M., Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep 2011;13:163-72.
40. Sowers JR., Whaley-Connell A., Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009;150:776-83.
41. Vinson GP., Coghlan JP. Expanding view of aldosterone action., with an emphasis on rapid action. Clin Exp Pharmacol Physiol 2010;37:410-6.
42. Caprio M., Feve B., Claes A., Viengchareun S., Lombes M., Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB 2007;21: 2185-94.
43. Hintikka J., Niskanen L., Koivumaa-Honkanen H., Tolmunen T., Honkalampi K., Lehto SM., Viinamaki H. Hypogonadism., decreased sexual desire., and long-term depression in middle-aged men. J Sex Med 2009;6:2049-57.
44. Shores MM., Kivlahan DR., Sadak TI., Li EJ., Matsumoto AM. A randomized., double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 2009;70:1009-16.
45. Heinemann LA. Aging Males' Symptoms scale: a standardized instrument for the practice. J Endocrinol Invest 2005;28:34-8.
46. Moore C., Huebler D., Zimmermann T., Heinemann LA., Saad F., Thai DM. The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency. Eur Urol 2004;46:80-7.
47. Vermeulen A., Verdonck L., Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
48. Daig I., Heinemann LA., Kim S., Leungwattanakij S., Badia X., Myon E., Moore C., Saad F., Potthoff P., Thai do M. The Aging Males' Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003;1:77.
49. Saad F., Aversa A., Isidori AM., Zafalon L., Zitzmann M., Gooren L. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol 2011;165:675-85.
50. Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R., Miceli M., Mammi C., Piepoli M., Fini M., Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity., skeletal muscle performance., insulin resistance., and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009;54:919-27.
51. Malkin CJ., Channer KS., Jones TH. Testosterone and heart failure. Curr Opin Endocrinol Diabetes Obes 2011;17:262-8.
52. Jones TH., Saad F. The effects of testosterone on risk factors for., and the mediators of., the atherosclerotic process. Atherosclerosis 2009;207:318-27.
53. Jones TH., Arver S., Behre HM., Buvat J., Meuleman E., Moncada I., Morales AM., Volterrani M., Yellowlees A., Howell JD., Channer KS., TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-37.
54. Kau MM., Lo MJ., Wang SW., Tsai SC., Chen JJ., Chiao YC., Yeh JY., Lin H., Shum AY., Fang VS., Ho LT., Wang PS. Inhibition of aldosterone production by testosterone in male_ rats. Metabolism 1999;48:1108-14.
55. Heufelder AE., Saad F., Bunck MC., Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-33.
56. Aversa A., Bruzziches R., Francomano D., Rosano G., Isidori AM., Lenzi A., Spera G. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized., double-blind, placebo-controlled study. J Sex Med 2010;7:3495-503.